Myriad Genetics (MYGN) enters an agreement with Pharma Mar, a leader in the development of...


Myriad Genetics (MYGN) enters an agreement with Pharma Mar, a leader in the development of marine-derived drugs, to conduct testing on patients to be enrolled in a Phase II clinical study of PM1183, a drug which induces double-stranded DNA breaks to cause cell death. Shares +0.4% AH.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs